Mind the gap from research laboratory to clinic: Challenges and opportunities for next-generation assays in human diseases. Issue 37 (31st August 2021)

• Record Type: Journal Article
• Authors: D'Souza, M. Patricia; Palin, Amy C.; Calder, Thomas; Golding, Hana; Kleinstein, Steven H.; Milliken, Erin L.; O'Connor, David; Tomaras, Georgia; Warren, Jon; Boggiano, Cesar
• Is Part Of: Vaccine. Volume 39:Issue 37(2021)
• Page Start: 5233
• Page End: 5239
• Publication Date: 2021-08-31
• Subjects: Vaccine -- HIV -- Tuberculosis -- Influenza -- SARS-CoV-2 -- Assay -- Technology; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.07.071
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Modern vaccinology has experienced major conceptual and technological advances over the past 30 years. These include atomic-level structures driving immunogen design, new vaccine delivery methods, powerful adjuvants, and novel animal models. In addition, utilizing advanced assays to learn how the immune system senses a pathogen and orchestrates protective immunity has been critical in the design of effective vaccines and therapeutics. The National Institute of Allergy and Infectious Diseases of the National Institutes of Health convened a workshop in September 2020 focused on next generation assays for vaccine development (Table 1 ). The workshop focused on four critical pathogens: severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and human immunodeficiency virus (HIV)—which have no licensed vaccines—and tuberculosis (TB) and influenza—both of which are in critical need of improved vaccines. The goal was to share progress and lessons learned, and to identify any commonalities that can be leveraged to design vaccines and therapeutics.